Skip to content
value.today

Cancer Genetics Inc.

Total raised
$33 M
5 rounds on record
Latest round
$10 M
Feb 2021
First round on record
Apr 2010
Today
Private
No later event on record

Funding rounds

5 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Cancer Genetics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2021$10 MNo. 5$10 to $50 million

Cancer Genetics Inc.: Raise no. 5, Feb 2021

Investors in this round

6 investors had bought by the notice of Feb 3, 2021: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Cancer Genetics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$775,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • John A. Roberts · Executive Officer
  • Edmund Cannon · Director
  • Franklyn G. Prendergast · Director
  • Geoffrey G. Harris · Director
  • Howard G. McLeod · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co., LLC (CRD 375) · New York, New YorkSold in CA, IL, NV, NY

Remarks in the notice

  • On fees: “Excludes the value of up to 165,517 warrants issued to the Placement Agent exercisable at $4.5313 per share.”
  • On the use of proceeds: “Some of the proceeds may be used for general working capital purposes which may include the payment of salaries and other fees to those listed in Item 3.”

Signed by John A. Roberts, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Feb 3, 2021. Read the notice at the SEC.

equity, optionsSEC
Mar 2017$6 MNo. 4$2 to $10 million

Cancer Genetics Inc.: Raise no. 4, Mar 2017

Investors in this round

3 investors had bought by the notice of Mar 27, 2017: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Cancer Genetics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$6 M of $6 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • John A. Roberts · Executive Officer
  • Panna L. Sharma · Executive Officer, Director
  • Edmund L. Cannon · Director
  • Franklyn G. Prendergast · Director
  • Geoffrey J. Harris · Director
  • Howard J. McLeod · Director
  • John L. Pappajohn · Director
  • Michael J. Welsh · Director
  • Raju S.K. Chaganti · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Excludes proceeds to be received from exercise of warrants.”
  • On the use of proceeds: “Some of the proceeds may be used for general working capital purposes which may include the payment of salaries and other fees to those listed in Item 3.”

Signed by John A. Roberts, Chief Operating Officer and EVP. Source: SEC Form D, newest notice filed Mar 27, 2017. Read the notice at the SEC.

debt, optionsSEC
Sep 2016$6 MNo. 3$2 to $10 million

Cancer Genetics Inc.: Raise no. 3, Sep 2016

Investors in this round

16 investors had bought by the notice of Dec 5, 2016: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Cancer Genetics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$6 M of $6 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
$5 million to $25 million
Sales commissions
$385,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Edward J. Sitar · Executive Officer
  • John A. Roberts · Executive Officer
  • Panna L. Sharma · Executive Officer, Director
  • Raju S.K. Chaganti · Executive Officer, Director
  • Edmund L. Cannon · Director
  • Franklyn G. Prendergast · Director
  • Geoffrey J. Harris · Director
  • Howard J. McLeod · Director
  • John L. Pappajohn · Director
  • Michael J. Welsh · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. WainWright & Co., LLC (CRD 375) · New York, New YorkSold in CA, FL, IA, IL, MA, MD, MN, ND, NJ, NY, TX, WI

Remarks in the notice

  • On fees: “Excludes 137,500 placement agent warrants. Additionally, does not include additional compensation to placement agent re: tail fees pursuant to future transactions.”
  • On the amounts: “Excludes proceeds totaling up to $3,093,750 from the exercise of the warrants.”
  • On the use of proceeds: “Some of the proceeds may be used for general working capital purposes which may include the payment of salaries and other fees to those listed in Item 3.”

Signed by Edward J. Sitar, Chief Financial Officer. Source: SEC Form D, newest notice filed Dec 5, 2016. Read the notice at the SEC.

optionsSEC
May 2016$5 MNo. 2$2 to $10 million

Cancer Genetics Inc.: Raise no. 2, May 2016

Investors in this round

41 investors had bought by the notice of May 25, 2016: 41 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Cancer Genetics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
$5 million to $25 million
Sales commissions
$350,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Edward J. Sitar · Executive Officer
  • Panna L. Sharma · Executive Officer, Director
  • Raju S.K. Chaganti · Executive Officer, Director
  • Edmund L. Cannon · Director
  • Franklyn G. Prendergast · Director
  • Geoffrey J. Harris · Director
  • Howard J. McLeod · Director
  • John L. Pappajohn · Director
  • Michael J. Welsh · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. WainWright & Co., LLC (CRD 375) · New York, New YorkSold in CA, FL, IA, IL, MA, MD, MN, ND, NJ, NY, TX, WI

Remarks in the notice

  • On fees: “Excludes 123,391 placement agent warrants. Additionally, does not include additional compensation to placement agent re: tail fees pursuant to future transactions.”
  • On the amounts: “Excludes proceeds totaling up to $2,776,297.50 from the exercise of the warrants.”
  • On the use of proceeds: “Some of the proceeds may be used for general working capital purposes which may include the payment of salaries and other fees to those listed in Item 3.”

Signed by Edward J. Sitar, Chief Financial Officer. Source: SEC Form D, newest notice filed May 25, 2016. Read the notice at the SEC.

optionsSEC
Apr 2010$7 MNo. 1$2 to $10 million

Cancer Genetics Inc.: Raise no. 1, Apr 2010

Investors in this round

42 investors had bought by the notice of Nov 1, 2010: 42 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Cancer Genetics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$7 M of $10 M offered; $3 M still to sell
Smallest investment taken
$10,000
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
$5 million to $25 million
Sales commissions
$6,620,620
Finders' fees
none
Paid to its own people
$460,000 (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Panna Sharma · Executive Officer, Director
  • Raju Chaganti · Executive Officer, Director
  • Andrew Pecora · Director
  • Edmund Cannon · Director
  • John Pappajohn · Director
  • Riccardo Dalla-Favera · Director
  • Tommy Thompson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Allen Partners (CRD 36518) · broker-dealer Portfolio Advisors Alliance, Inc. (CRD 101680) · New York, New YorkSold in AL, AZ, CA, CO, CT, DC, DE, FL, GA, HI, IA, IL, IN, KY, LA, MA, MD, ME, MI, MN, MO, MS, NC, NE, NH, NJ, NV, NY, OH, OK, OR, PA, PR, SC, TX, UT, VA, VT, WA, WI, WV, WY
  • Felix Investments, LLC (CRD 148441) · New York, New YorkSold in all US states
  • Garden State Securities, Inc. (CRD 10083) · broker-dealer Portfolio Advisors Alliance, Inc. (CRD 101680) · Wall Township, New JerseySold in all US states

Signed by Panna Sharma, President. Source: SEC Form D and 1 amendment, newest notice filed Nov 1, 2010. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Cancer Genetics Inc. chose not to state its revenue in its newest notice of a funding round (Feb 2021).

    SEC Form D · Feb 2021

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Feb 2021

That is all the official record says: Cancer Genetics Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

1 named in official filings. Open an investor to see everything it has backed.

Investors in Cancer Genetics Inc.
InvestorKindAmountRoundRoleSource
John PappajohnPersonnot statednot statedHeld Series A-1 preferred stock, director (Form 3, 2013)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 42 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Cancer Genetics Inc.
NameRoleNamed in
John A. RobertsExecutive officerFeb 2021
Panna L. SharmaExecutive officerMar 2017
Edward J. SitarExecutive officerDec 2016
Raju S.K. ChagantiExecutive officerDec 2016
Panna SharmaExecutive officerNov 2010
Raju ChagantiExecutive officerNov 2010
Edmund CannonDirectorFeb 2021
Franklyn G. PrendergastDirectorFeb 2021
Geoffrey G. HarrisDirectorFeb 2021
Howard G. McLeodDirectorFeb 2021
Edmund L. CannonDirectorMar 2017
Geoffrey J. HarrisDirectorMar 2017
Howard J. McLeodDirectorMar 2017
John L. PappajohnDirectorMar 2017
Michael J. WelshDirectorMar 2017
Panna L. SharmaDirectorMar 2017
Raju S.K. ChagantiDirectorMar 2017
Andrew PecoraDirectorNov 2010
John PappajohnDirectorNov 2010
Panna SharmaDirectorNov 2010
Raju ChagantiDirectorNov 2010
Riccardo Dalla-FaveraDirectorNov 2010
Tommy ThompsonDirectorNov 2010